Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) Patients
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
This 2 step study aims to establish a tolerable dose level and regimen of RAD001 in patients
with advanced NCLC not previously treated with systemic therapy. In step 1 of this study, RAD
001 is given in combination with carboplatin and paclitaxel and in Step 2 RAD001 is given in
combination with carboplatin, paclitaxel and bevacizumab